Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
OVERVIEW | |
---|---|
Interface: | Ovid |
Databases: | Embase 1974 to present |
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to present | |
Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid. | |
Date of Search: | October 7, 2016 |
Alerts: | Bi-weekly (twice monthly) search updates until February 15, 2017 |
Study Types: | No search filters were applied |
Limits: | No date or language limits were used |
Conference abstracts were excluded | |
SYNTAX GUIDE | |
/ | At the end of a phrase, searches the phrase as a subject heading |
MeSH | Medical Subject Heading |
exp | Explode a subject heading |
* | Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings |
.ti | Title |
.ab | Abstract |
.ot | Original title |
.hw | Heading word; usually includes subject headings and controlled vocabulary |
.kf | Author keyword heading word (MEDLINE) |
.kw | Author keyword (Embase) |
.pt | Publication type |
.rn | CAS registry number |
.nm | Name of substance word |
ppez | Ovid database code; MEDLINE Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE Daily and Ovid MEDLINE 1946 to Present |
oemezd | Ovid database code; Embase 1974 to present, updated daily |
MULTI-DATABASE STRATEGY | |
---|---|
# | Searches |
1 | Ustekinumab/ |
2 | (815610-63-0 or 949907-93-1 or FU77B4U5Z0).rn,nm. |
3 | (Stelara* or ustekinumab* or CNTO 1275 or CNTO1275).ti,ab,rn,nm,kf,hw,ot. |
4 | or/1–3 |
5 | Crohn disease/ |
6 | (crohn* or granulomatous colitis or granulomatous enteritis or regional enteritis or regional ileitis or regional ileitides or terminal ileitis or ileocolitis or cleron disease* or enteritis regionalis or regional enterocolitis).ti,ab,kf. |
7 | or/5–6 |
8 | 4 and 7 |
9 | 8 use ppez |
10 | *Ustekinumab/ |
11 | (Stelara* or Ustekinumab* or CNTO 1275 or CNTO1275).ti,ab,kw. |
12 | or/10–11 |
13 | exp Crohn disease/ |
14 | (crohn* or granulomatous colitis or granulomatous enteritis or regional enteritis or regional ileitis or regional ileitides or terminal ileitis or ileocolitis or cleron disease* or enteritis regionalis or regional enterocolitis).ti,ab,kw. |
15 | or/13–14 |
16 | 12 and 15 |
17 | 16 use oemezd |
18 | conference abstract.pt. |
19 | 17 not 18 |
20 | 9 or 19 |
21 | remove duplicates from 20 |
OTHER DATABASES | |
---|---|
PubMed | A limited PubMed search was performed to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used. |
Trial registries (Clinicaltrials.gov and others) | Same keywords, limits used as per MEDLINE search. |
Grey Literature
Dates for Search: | September – October 2016 |
Keywords: | Stelara (ustekinumab); Crohn’s disease |
Limits: | No date or language limits used |
Relevant websites from the following sections of the CADTH grey literature checklist Grey Matters: a practical tool for searching health-related grey literature (https://www.cadth.ca/grey-matters) were searched:
- Health Technology Assessment Agencies
- Health Economics
- Clinical Practice Guidelines
- Drug and Device Regulatory Approvals
- Advisories and Warnings
- Drug Class Reviews
- Databases (free)
- Internet Search.
- LITERATURE SEARCH STRATEGY - Ustekinumab (Stelara)LITERATURE SEARCH STRATEGY - Ustekinumab (Stelara)
- VALIDITY OF OUTCOME MEASURES - Glycerol Phenylbutyrate (Ravicti)VALIDITY OF OUTCOME MEASURES - Glycerol Phenylbutyrate (Ravicti)
- COST COMPARISON - Glycerol Phenylbutyrate (Ravicti)COST COMPARISON - Glycerol Phenylbutyrate (Ravicti)
- LIMITATIONS OF MANUFACTURER’S SUBMISSION - Glycerol Phenylbutyrate (Ravicti)LIMITATIONS OF MANUFACTURER’S SUBMISSION - Glycerol Phenylbutyrate (Ravicti)
- REFERENCE - Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day)REFERENCE - Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day)
Your browsing activity is empty.
Activity recording is turned off.
See more...